Arcus Biosciences Provides Update on Clinical Programs, Including Key 2022 Milestones

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today provided updates on clinical programs and key milestones anticipated in 2022. “Our priorities for 2022 are clear and unambiguous—to flawlessly execute on the expansion of our...

Click to view original post